Skip to main content

Covid-19 vaccine trial begins at Mumbai hospital today

By Unknown

The first dose of Covid-19 vaccine candidate developed by the Oxford University and AstraZeneca will on Saturday be administered to three volunteers at the King Edward Memorial (KEM) Hospital in Mumbai while 10 more volunteers have been selected for the clinical trial.

Another Mumbai hospital BYL Nair will commence the process of clinical trials from Monday.

Volunteers given the vaccine dose at the KEM hospital will be checked regularly and within 29 days a second dose will be given to them.


All three volunteers who will get the shot today have been screened to rule out any underlying health issues, KEM Hospital officials said. They also underwent RT-PCR and antibody testing. “The three participants have been screened after their consent and they don’t have any comorbidity. As per randomisation, out of every four participants, one will receive placebo (false drug),” said Dr Hemant Deshmukh, Dean, KEM Hospital.

According to Indian Council of Medical Research (ICMR) guidelines, each of the volunteers has been covered with Rs 1crore life insurance in case of death due to any side effects during the trial. They have also been covered under Rs 50lakh medical insurance if they develop any adverse effect from the vaccine.

“We will administer the first dose of Covid-19 vaccine to the three volunteers on Saturday” Suresh Kakani, additional municipal commissioner, Brihanmumbai Municipal Corporation (BMC) said. He added that 10 more people will be screened on Saturday which will take the number of volunteers to 23. “We will check how they respond after the inoculation and test them for antibodies,” he said.

After the volunteers are given the shot, they will have to stay at the hospital for two hours to check if they are having any complications,

The vaccine induces a strong immune response. It provokes a T cell (white blood cells that can attack cells infected with the coronavirus) response within 14 days of the dose, and an antibody response within 28 days.


Comments

Post a Comment

Popular posts from this blog

Iran, Russia Discussing Joint Production Of COVID-19 Vaccine

By Unknown
Iran and Russia's sovereign wealth fund RDIF are discussing the joint production of a vaccine against COVID-19, Russian news agencies cited the Iranian ambassador to Moscow as saying on Friday. "We are holding talks, I spoke with the head of RDIF Kirill Dmitriev, our officials have held several rounds of consultations and we announced that we will co-operate," Ambassador to Moscow Kazem Jalali was cited as saying. Thus far, Russia has struck a manufacturing partnership deal with India, which is due to produce 300 million doses of the 'Sputnik-V' vaccine domestically. It is also discussing such partnerships with several other countries, including Brazil.
Post a Comment
Read more

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

Russia's Covid-19 vaccine Sputnik V available to public now: State media

By Unknown
First batches of Russia's Covid vaccine Sputnik V have entered "civil circulation" in capital Moscow, state media reported on Thursday. While details on the process were not immediately available, Russia has repeatedly stressed on producing the vaccine at the earliest, a belief met with international scepticism. Earlier this month, the Russian health ministry had said that batches of the Covid-19 vaccine were being produced for public distribution and would be supplied to different regions soon. "The first batch of the vaccine for preventing the novel coronavirus infection, Gam-COVID-Vac (Sputnik V) developed by the Gamaleya Research Institute of Epidemiology and Microbiology of the Russian Health Ministry passed the required quality tests in the laboratories of Roszdravnadzor (the Federal Service for Surveillance in Healthcare) and was produced for civilian circulation. In the near future the supplies of the first batches of the vaccine to the regions are expected...
Post a Comment
Read more